ODI Pharma AB: Publication of interim report report Q3 2022/2023
ODI Pharma AB (“ODI” or the “Company”) hereby publishes its interim report for the period July 2022 – March 2023. The report is available as an attached document to this press release and on the Company’s website (www.odipharma.com). Below is a summary of the report.Third quarter (2023-01-01 – 2023-03-31) The Group's net sales amounted to SEK 10,801 (71,298) The Group's loss after financial items amounted to SEK -942,440 (-2,344,281) Result per share amounted to SEK -0.06 (-0.15)* Nine months (2022-07-01 – 2023-03-31) The Group’s net sales amounted to SEK 112,083 (529,918)